Targeting the tumour stroma to increase efficacy of chemo- and radiotherapy

Clinical and Translational Oncology

Volumn 11, Issue 2, 2009, Pages 75-81

  Chometon, Gretel ^a   Jendrossek, Verena ^a  

^a UNIVERSITY OF DUISBURG ESSEN   (Germany)

Author keywords

Microenvironment; Radiotherapy; Reactive stroma; Treatment resistance

Indexed keywords

ANGIOGENESIS INHIBITOR; ANTINEOPLASTIC AGENT; BETA1 INTEGRIN; CTCE 9908; MAMMALIAN TARGET OF RAPAMYCIN; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; SCLEROPROTEIN; UNCLASSIFIED DRUG;

ARTICLE; CANCER ASSOCIATED FIBROBLAST; CANCER GROWTH; CANCER INVASION; CANCER RADIOTHERAPY; CANCER SURVIVAL; CARCINOGENESIS; CELL ADHESION; CELL DEATH; CELL PROLIFERATION; DRUG TARGETING; EXTRACELLULAR MATRIX; FIBROBLAST; HUMAN; METASTASIS; MICROENVIRONMENT; SIGNAL TRANSDUCTION; STROMA; STROMA CELL; TUMOR; VASCULAR ENDOTHELIUM; ANIMAL; BIOLOGICAL MODEL; CYTOLOGY; DRUG RESISTANCE; METABOLISM; MULTIMODALITY CANCER THERAPY; NEOPLASM; REVIEW;

ANIMALS; COMBINED MODALITY THERAPY; DRUG RESISTANCE, NEOPLASM; EXTRACELLULAR MATRIX; FIBROBLASTS; HUMANS; MODELS, BIOLOGICAL; NEOPLASMS; STROMAL CELLS;

EID: 67449087327     PISSN: 1699048X     EISSN: None     Source Type: Journal    
DOI: 10.1007/s12094-009-0317-y     Document Type: Article

References (101)

1. Brown JM, Attardi LD (2005) The role of apoptosis in cancer development and treatment response. Nat Rev Cancer 5:231-237
2. Belka C, Jendrossek V, Pruschy M et al (2004) Apoptosis-modulating agents in combination with radiotherapy-current status and outlook. Int J Radiat Oncol Biol Phys 58:542-554
3. Fesik SW (2005) Promoting apoptosis as a strategy for cancer drug discovery. Nat Rev Cancer 5:876-885
4. Marini P, Schmid A, Jendrossek V et al (2005) Irradiation specifically sensitises solid tumour cell lines to TRAIL mediated apoptosis. BMC Cancer 5:5
5. Marini P, Denzinger S, Schiller D et al (2006) Combined treatment of colorectal tumours with agonistic TRAIL receptor antibodies HGS-ETR1 and HGS-ETR2 and radiotherapy: Enhanced effects in vitro and dose-dependent growth delay in vivo. Oncogene 25:5145-5154
6. Niyazi M, Marini P, Daniel PT et al (2009) Efficacy of a triple treatment with irradiation, agonistic TRAIL receoptor antibodies and EGFR blockade. Strahlenther Onkol 185:8-18
7. Hanahan D, Weinberg RA (2000) The hallmarks of cancer. Cell 100:57-70
8. Fearon ER, Vogelstein B (1990) A genetic model for colorectal tumorigenesis. Cell 61:759-767
9. Evan GI, Vousden KH (2001) Proliferation, cell cycle and apoptosis in cancer. Nature 411:342-348
10. Lowe SW, Cepero E, Evan G (2004) Intrinsic tumour suppression. Nature 432:307-315
11. Bartkova J, Rezaei N, Liontos M et al (2006) Oncogene-induced senescence is part of the tumorigenesis barrier imposed by DNA damage checkpoints. Nature 444:633-637
12. Raff MC (1992) Social controls on cell survival and cell death. Nature 356:397-400
13. Balkwill F (2005) Immunology for the next generation. Nat Rev Immunol 5:509-512
14. Giancotti FG, Ruoslahti E (1999) Integrin signaling. Science 285:1028-1032
15. Gatenby RA, Gillies RJ (2008) A microenvironmental model of carcinogenesis. Nat Rev Cancer 8:56-61
16. Hendrix MJ, Seftor EA, Seftor RE et al (2007) Reprogramming metastatic tumour cells with embryonic microenvironments. Nat Rev Cancer 7:246-255
17. Dvorak HF (1986) Tumors: Wounds that do not heal. Similarities between tumor stroma generation and wound healing. N Engl J Med 315:1650-1659
18. Liotta LA, Kohn EC (2001) The microenvironment of the tumour-host interface. Nature 411:375-379
19. Mueller MM, Fusenig NE (2004) Friends or foes - bipolar effects of the tumour stroma in cancer. Nat Rev Cancer 4:839-849
20. Frisch SM, Francis H (1994) Disruption of epithelial cell-matrix interactions induces apoptosis. J Cell Biol 124:619-626
21. Lowe SW, Lin AW (2000) Apoptosis in cancer. Carcinogenesis 21:485-495
22. Igney FH, Krammer PH (2002) Death and antideath: Tumour resistance to apoptosis. Nat Rev Cancer 2:277-288
23. Timpl R, Brown JC (1996) Supramolecular assembly of basement membranes. Bioessays 18:123-32
24. Aumailley M, Gayraud B (1998) Structure and biological activity of the extracellular matrix. J Mol Med 76:253-265
25. Zamir E, Geiger B (2001) Components of cellmatrix adhesions. J Cell Sci 114:3577-3579
26. Watt FM (2002) Role of integrins in regulating epidermal adhesion, growth and differentiation. EMBO J 21:3919-3926
27. van der Flier A, Sonnenberg A (2001) Function and interactions of integrins. Cell Tissue Res 305:285-298
28. Hynes RO (2002) Integrins: Bidirectional, allosteric signaling machines. Cell 110:673-687
29. Martin KH, Slack JK, Boerner SA et al (2002) Integrin connections map: to infinity and beyond. Science 296:1652-1653
30. Yamada KM, Even-Ram S (2002) Integrin regulation of growth factor receptors. Nat Cell Biol 4:E75-76
31. Fridman R, Giaccone G, Kanemoto T et al (1990) Reconstituted basement membrane (matrigel) and laminin can enhance the tumorigenicity and the drug resistance of small cell lung cancer cell lines. Proc Natl Acad Sci U S A 87:6698-6702
32. Sethi T, Rintoul RC, Moore SM et al (1999) Extracellular matrix proteins protect small cell lung cancer cells against apoptosis: A mechanism for small cell lung cancer growth and drug resistance in vivo. Nat Med 5:662-668
33. Cordes N, Beinke C (2004) Fibronectin alters cell survival and intracellular signaling of confluent A549 cultures after irradiation. Cancer Biol Ther 3:47-53
34. Mueller MM, Fusenig NE (2002) Tumor-stroma interactions directing phenotype and progression of epithelial skin tumor cells. Differentiation 70:486-497
35. Frisch SM, Ruoslahti E (1997) Integrins and anoikis. Curr Opin Cell Biol 9:701-706
36. Puthalakath H, Villunger A, O'Reilly LA et al (2001) Bmf: A proapoptotic BH3-only protein regulated by interaction with the myosin V actin motor complex, activated by anoikis. Science 293:1829-1832
37. Khwaja A, Rodriguez-Viciana P, Wennstrom S et al (1997) Matrix adhesion and Ras transformation both activate a phosphoinositide 3-OH kinase and protein kinase B/Akt cellular survival pathway. EMBO J 16:2783-2793
38. Gilmore AP (2005) Anoikis. Cell Death Differ 12[Suppl 2]:1473-1477
39. Lewis JM, Truong TN, Schwartz MA (2002) Integrins regulate the apoptotic response to DNA damage through modulation of p53. Proc Natl Acad Sci U S A 99:3627-3632
40. Hazlehurst LA, Landowski TH, Dalton WS (2003) Role of the tumor microenvironment in mediating de novo resistance to drugs and physiological mediators of cell death. Oncogene 22:7396-7402
41. Miyamoto H, Murakami T, Tsuchida K et al (2004) Tumor-stroma interaction of human pancreatic cancer: Acquired resistance to anticancer drugs and proliferation regulation is dependent on extracellular matrix proteins. Pancreas 28:38-44
42. Uhm JH, Dooley NP, Kyritsis AP et al (1999) Vitronectin, a glioma-derived extracellular matrix protein, protects tumor cells from apoptotic death. Clin Cancer Res 5:1587-1594
43. Damiano JS, Hazlehurst LA, Dalton WS (2001) Cell adhesion-mediated drug resistance (CAMDR) protects the K562 chronic myelogenous leukemia cell line from apoptosis induced by BCR/ABL inhibition, cytotoxic drugs, and gamma-irradiation. Leukemia 15:1232-1239
44. Cao C, Mu Y, Hallahan DE, Lu B (2004) XIAP and survivin as therapeutic targets for radiation sensitization in preclinical models of lung cancer. Oncogene 23:7047-7052
45. Cordes N, Seidler J, Durzok R et al (2006) Beta 1-integrin-mediated signaling essentially contributes to cell survival after radiation-induced genotoxic injury. Oncogene 25:1378-1390
46. Serebriiskii I, Castello-Cros R, Lamb A et al (2008) Fibroblast-derived 3D matrix differentially regulates the growth and drug-responsiveness of human cancer cells. Matrix Biol 27:573-585
47. Fornaro M, Plescia J, Chheang S et al (2003) Fibronectin protects prostate cancer cells from tumor necrosis factor-alpha-induced apoptosis via the AKT/survivin pathway. J Biol Chem 278:50402-50411
48. Matter ML, Ruoslahti E (2001) A signaling pathway from the alpha5beta1 and alpha(v)beta3 integrins that elevates bcl-2 transcription. J Biol Chem 276:27757-27763
49. Inohara N, Koseki T, Hu Y et al (1997) CLARP, a death effector domain-containing protein interacts with caspase-8 and regulates apoptosis. Proc Natl Acad Sci U S A 94:10717-10722
50. Han S, Khuri FR, Roman J (2006) Fibronectin stimulates non-small cell lung carcinoma cell growth through activation of Akt/mammalian target of rapamycin/S6 kinase and inactivation of LKB1/AMP-activated protein kinase signal pathways. Cancer Res 66:315-323
51. Bhowmick NA, Neilson EG, Moses HL (2004) Stromal fibroblasts in cancer initiation and progression. Nature 432:332-337
52. Desmouliere A, Guyot C, Gabbiani G (2004) The stroma reaction myofibroblast: A key player in the control of tumor cell behavior. Int J Dev Biol 48:509-517
53. Hinz B, Phan SH, Thannickal VJ et al (2007) The myofibroblast: One function, multiple origins. Am J Pathol 170:1807-1816
54. Tuxhorn JA, McAlhany SJ, Dang TD et al (2002) Stromal cells promote angiogenesis and growth of human prostate tumors in a differential reactive stroma (DRS) xenograft model. Cancer Res 62:3298-3307
55. Giulianelli S, Cerliani JP, Lamb CA et al (2008) Carcinoma-associated fibroblasts activate progesterone receptors and induce hormone independent mammary tumor growth: A role for the FGF-2/FGFR-2 axis. Int J Cancer 123:2518-2531
56. Olumi AF, Grossfeld GD, Hayward SW et al (1999) Carcinoma-associated fibroblasts direct tumor progression of initiated human prostatic epithelium. Cancer Res 59:5002-5011
57. Micke P, Ostman A (2004) Tumour-stroma interaction: Cancer-associated fibroblasts as novel targets in anti-cancer therapy? Lung Cancer 45[Suppl 2]:S163-175
58. Kalluri R, Zeisberg M (2006) Fibroblasts in cancer. Nat Rev Cancer 6:392-401
59. Fukumura D, Xavier R, Sugiura T et al (1998) Tumor induction of VEGF promoter activity in stromal cells. Cell 94:715-725
60. Serini G, Bochaton-Piallat ML, Ropraz P et al (1998) The fibronectin domain ED-A is crucial for myofibroblastic phenotype induction by transforming growth factor-beta1. J Cell Biol 142:873-881
61. Wang J, Yu W, Cai Y et al (2008) Altered fibroblast growth factor receptor 4 stability promotes prostate cancer progression. Neoplasia 10:847-856
62. Orimo A, Gupta PB, Sgroi DC et al (2005) Stromal fibroblasts present in invasive human breast carcinomas promote tumor growth and angiogenesis through elevated SDF-1/CXCL12 secretion. Cell 121:335-348
63. Noma K, Smalley KS, Lioni M et al (2008) The essential role of fibroblasts in esophageal squamous cell carcinoma-induced angiogenesis. Gastroenterology 134:1981-1993
64. Loeffler M, Kruger JA, Niethammer AG, Reisfeld RA (2006) Targeting tumor-associated fibroblasts improves cancer chemotherapy by increasing intratumoral drug uptake. J Clin Invest 116:1955-1962
65. Shekhar MP, Santner S, Carolin KA, Tait L (2007) Direct involvement of breast tumor fibroblasts in the modulation of tamoxifen sensitivity. Am J Pathol 170:1546-1560
66. Santana P, Pena LA, Haimovitz-Friedman A et al (1996) Acid sphingomyelinase-deficient human lymphoblasts and mice are defective in radiationinduced apoptosis. Cell 86:189-199
67. Fuks Z, Kolesnick R (2005) Engaging the vascular component of the tumor response. Cancer Cell 8:89-91
68. Bianco R, Rosa R, Damiano V et al (2008) Vascular endothelial growth factor receptor-1 contributes to resistance to anti-epidermal growth factor receptor drugs in human cancer cells. Clin Cancer Res 14:5069-5080
69. Garcia-Barros M, Lacorazza D, Petrie H et al (2004) Host acid sphingomyelinase regulates microvascular function not tumor immunity. Cancer Res 64:8285-8291
70. Moeller BJ, Cao Y, Li CY, Dewhirst MW (2004) Radiation activates HIF-1 to regulate vascular radiosensitivity in tumors: Role of reoxygenation, free radicals, and stress granules. Cancer Cell 5:429-441
71. Moeller BJ, Dewhirst MW (2006) HIF-1 and tumour radiosensitivity. Br J Cancer 95:1-5
72. Bonnaud S, Niaudet C, Pottier G et al (2007) Sphingosine-1-phosphate protects proliferating endothelial cells from ceramide-induced apoptosis but not from DNA damage-induced mitotic death. Cancer Res 67:1803-1811
73. Guo W, Giancotti FG (2004) Integrin signalling during tumour progression. Nat Rev Mol Cell Biol 5:816-826
74. Cordes N, Park CC (2007) Beta1 integrin as a molecular therapeutic target. Int J Radiat Biol 83:753-760
75. Hess F, Estrugo D, Fischer A et al (2007) Integrin-linked kinase interacts with caspase-9 and -8 in an adhesion-dependent manner for promoting radiation-induced apoptosis in human leukemia cells. Oncogene 26:1372-1384
76. Zutter MM (2007) Integrin-mediated adhesion: Tipping the balance between chemosensitivity and chemoresistance. Adv Exp Med Biol 608:87-100
77. Bisanz K, Yu J, Edlund M et al (2005) Targeting ECM-integrin interaction with liposome-encapsulated small interfering RNAs inhibits the growth of human prostate cancer in a bone xenograft imaging model. Mol Ther 12:634-643
78. Park CC, Zhang H, Pallavicini M et al (2006) Beta1 integrin inhibitory antibody induces apoptosis of breast cancer cells, inhibits growth, and distinguishes malignant from normal phenotype in three dimensional cultures and in vivo. Cancer Res 66:1526-1535
79. Schwartz MA, McRoberts K, Coyner M et al (2008) Integrin agonists as adjuvants in chemotherapy for melanoma. Clin Cancer Res 14:6193-6197
80. Kalluri R (2003) Basement membranes: Structure, assembly and role in tumour angiogenesis. Nat Rev Cancer 3:422-433
81. Baluk P, Morikawa S, Haskell A et al (2003) Abnormalities of basement membrane on blood vessels and endothelial sprouts in tumors. Am J Pathol 163:1801-1815
82. Ortiz-Urda S, Garcia J, Green CL et al (2005) Type VII collagen is required for Ras-driven human epidermal tumorigenesis. Science 307:1773-1776
83. Tran M, Rousselle P, Nokelainen P et al (2008) Targeting a tumor-specific laminin domain critical for human carcinogenesis. Cancer Res 68:2885-2894
84. Topczewska JM, Postovit LM, Margaryan NV et al (2006) Embryonic and tumorigenic pathways converge via Nodal signaling: Role in melanoma aggressiveness. Nat Med 12:925-932
85. Bhowmick NA, Chytil A, Plieth D et al (2004) TGF-beta signaling in fibroblasts modulates the oncogenic potential of adjacent epithelia. Science 303:848-851
86. Kim SY, Lee CH, Midura BV et al (2008) Inhibition of the CXCR4/CXCL12 chemokine pathway reduces the development of murine pulmonary metastases. Clin Exp Metastasis 25:201-211
87. Guleng B, Tateishi K, Ohta M et al (2005) Blockade of the stromal cell-derived factor-1/CXCR4 axis attenuates in vivo tumor growth by inhibiting angiogenesis in a vascular endothelial growth factor-independent manner. Cancer Res 65:5864-5871
88. Fischer H, Taylor N, Allerstorfer S et al (2008) Fibroblast growth factor receptor-mediated signals contribute to the malignant phenotype of non-small cell lung cancer cells: Therapeutic implications and synergism with epidermal growth factor receptor inhibition. Mol Cancer Ther 7:3408-3419
89. Scott AM, Wiseman G, Welt S et al (2003) A Phase I dose-escalation study of sibrotuzumab in patients with advanced or metastatic fibroblast activation protein-positive cancer. Clin Cancer Res 9:1639-1647
90. Ohuchida K, Mizumoto K, Murakami M et al (2004) Radiation to stromal fibroblasts increases invasiveness of pancreatic cancer cells through tumorstromal interactions. Cancer Res 64:3215-3222
91. Kadenhe-Chiweshe A, Papa J, McCrudden KW et al (2008) Sustained VEGF blockade results in microenvironmental sequestration of VEGF by tumors and persistent VEGF receptor-2 activation. Mol Cancer Res 6:1-9
92. Crawford Y, Kasman I, Yu L et al (2009) PDGFC mediates the angiogenic and tumorigenic properties of fibroblasts associated with tumors refractory to anti-VEGF treatment. Cancer Cell 15:21-34
93. Kabakov AE, Makarova YM, Malyutina YV (2008) Radiosensitization of human vascular endothelial cells through Hsp90 inhibition with 17-N-allilamino-17-demethoxygeldanamycin. Int J Radiat Oncol Biol Phys 71:858-865
94. Ramakrishnan V, Bhaskar V, Law DA et al (2006) Preclinical evaluation of an anti-alpha5beta1 integrin antibody as a novel anti-angiogenic agent. J Exp Ther Oncol 5:273-286
95. Mulgrew K, Kinneer K, Yao XT et al (2006) Direct targeting of alphavbeta3 integrin on tumor cells with a monoclonal antibody, Abegrin. Mol Cancer Ther 5:3122-3129
96. Cretu A, Roth JM, Caunt M et al (2007) Disruption of endothelial cell interactions with the novel HU177 cryptic collagen epitope inhibits angiogenesis. Clin Cancer Res 13:3068-3078
97. Delbaldo C, Raymond E, Vera K et al (2008) Phase I and pharmacokinetic study of etaracizumab (Abegrin), a humanized monoclonal antibody against alphavbeta3 integrin receptor, in patients with advanced solid tumors. Invest New Drugs 26:35-43
98. Nabors LB, Mikkelsen T, Rosenfeld SS et al (2007) Phase I and correlative biology study of cilengitide in patients with recurrent malignant glioma. J Clin Oncol 25:1651-1657
99. Veeravagu A, Liu Z, Niu G et al (2008) Integrin alphavbeta3-targeted radioimmunotherapy of glioblastoma multiforme. Clin Cancer Res 14:7330-7339
100. Bhaskar V, Zhang D, Fox M et al (2007) A function blocking anti-mouse integrin alpha5beta1 antibody inhibits angiogenesis and impedes tumor growth in vivo. J Transl Med 5:61
101. He X, Fang L, Wang J et al (2008) Bryostatin-5 blocks stromal cell-derived factor-1 induced chemotaxis via desensitization and down-regulation of cell surface CXCR4 receptors. Cancer Res 68:8678-8686